TScan Therapeutics Past Earnings Performance
Past criteria checks 0/6
TScan Therapeutics's earnings have been declining at an average annual rate of -37.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 50.8% per year.
Key information
-37.4%
Earnings growth rate
88.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 50.8% |
| Return on equity | -59.1% |
| Net Margin | -423.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Revenue & Expenses BreakdownBeta
How TScan Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 21 | -89 | 26 | 0 |
| 30 Sep 23 | 17 | -88 | 26 | 0 |
| 30 Jun 23 | 16 | -82 | 25 | 0 |
| 31 Mar 23 | 17 | -73 | 24 | 0 |
| 31 Dec 22 | 14 | -66 | 20 | 0 |
| 30 Sep 22 | 13 | -62 | 19 | 0 |
| 30 Jun 22 | 12 | -61 | 18 | 0 |
| 31 Mar 22 | 11 | -57 | 16 | 0 |
| 31 Dec 21 | 10 | -49 | 14 | 0 |
| 30 Sep 21 | 8 | -42 | 12 | 0 |
| 30 Jun 21 | 6 | -34 | 10 | 0 |
| 31 Mar 21 | 3 | -29 | 8 | 0 |
| 31 Dec 20 | 1 | -26 | 7 | 0 |
Quality Earnings: TCRX is currently unprofitable.
Growing Profit Margin: TCRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TCRX is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare TCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TCRX has a negative Return on Equity (-59.14%), as it is currently unprofitable.